Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Wellbutrin XL · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Wellbutrin XL or placebo | PLACEBO_COMPARATOR | 1 arms - Wellbutrin XL or placebo |
| Name | Type | Description |
|---|---|---|
| Wellbutrin XL | DRUG | Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated. |
Inclusion Criteria: A subject must: 1. Be able to understand and sign a written informed consent 2. Be a premenopausal female between 20 and 50 years of age, inclusive 3. Use active birth control, and be non-lactating, with a negative urine pregnancy test 4. Have no evidence of mood or anxiety dis...
Wellbutrin XL is a small molecule drug being studied for Orgasmic Disorder and Depressive Disorder. It is developed by GSK plc. The drug is currently in Phase 2 clinical development for these conditions.
Wellbutrin XL is developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is being investigated for use in Orgasmic Disorder and Depressive Disorder.
Wellbutrin XL is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy for the studied indications.
Wellbutrin XL has been studied in clinical trials including NCT00248209, a Phase 2 trial for Female Orgasmic Disorder, and NCT00439868, a Phase 1 trial for Depressive Disorder. Both trials were completed in the United States.
Wellbutrin XL is a brand name for the drug bupropion, which is used to treat depression. However, the specific formulation and delivery mechanism of Wellbutrin XL may differ from other bupropion products.